SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Greenlee R, Murray T, Bolden S, Wingo P. Cancer Statistics, 2000. CA Cancer J Clin 2000; 50(1): 733.
  • 2
    Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999; 353(9160): 12537. [see also Comments]
  • 3
    Colombo M. Hepatitis C virus and hepatocellular carcinoma. Semin Liver Dis 1999; 19(3): 2639.
  • 4
    Seeff LB. Natural history of hepatitis C. Am J Med 1999; 107(6B): 10S15S.
  • 5
    Lee YT, Geer DA. Primary liver cancer: pattern of metastasis. J Surg Oncol 1987; 36(1): 2631.
  • 6
    Okuda K, Musha H, Nakajima Y, Kubo Y, Shimokawa Y, Nagasaki Y, et al. Clinicopathologic features of encapsulated hepatocellular carcinoma: a study of 26 cases. Cancer 1977; 40(3): 12405.
  • 7
    Kuhn JG. Pharmacology of irinotecan. Oncology (Huntingt) 1998; 12(8 Suppl 6 ): 3942.
  • 8
    Rosen LS. Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers. Oncology (Huntingt) 1998; 12(8 Suppl 6 ): 1039.
  • 9
    Jansen WJ, Zwart B, Hulscher ST, Giaccone G, Pinedo HM, Boven E. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer 1997; 70(3): 33540.
  • 10
    Matsuoka H, Yano K, Seo Y, Saito T, Tomoda H, Takiguchi S, Kono A. Cytotoxicity of CPT-11 for gastrointestinal cancer cells cultured on fixed-contact-sensitive plates. Anticancer Drugs 1995; 6(3): 4138.
  • 11
    Chabot GG, Robert J, Lokiec F, Canal P. [Irinotecan pharmacokinetics]. Bull Cancer 1998; Spec No: 1120. French.
  • 12
    Abigerges D, Armand JP, Chabot GG, DaCosta L, Fadel E, Cote C, Herait P, Gandia D. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86(6): 4469.
  • 13
    Cance WG, Stewart AK, Menck HR. The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985–1996. Cancer 2000; 88(4): 91220.
  • 14
    Okada S. Chemotherapy in hepatocellular carcinoma. Hepatogastroenterology 1998; 45 (3 Suppl): 125963.
  • 15
    O'Reilly E, Stuart K, Kemeny N, Steger C, Raeburn L, Sanz-Altamira P, et al.: A phase II trial of Irinotecan (CPT-11) in patients with advanced hepatocellular carcinomas (HCC) [Abstract 1026]. In: Progams/Proceedings American Society of Clinical Oncology 34th Annual Meeting, Los Angeles, CA, May 16–1998. Alexandria, VA: American Society of Clinical Oncology, 1998.
  • 16
    Alberts S, Mahoney M, Fishkin P, Burgart L, Cerap P, Sargent D, Nair S, Pitot H, Goldberg R. Toxicity of irinotecan (CPT-11) in patients (PTS) with advanced gallbladder (GB) or biliary (Bili) tumors: A North Central Cancer Treatment Group (NCCTG) Study. [Abstract 1166] In: Programs/Proceedings American Society of Clinical Oncology 36th Annual Meeting, New Orleans, LA, May 20–23, 2000. Alexandria, VA: American Society of Clinical Oncology, 2000.
  • 17
    Chu XY, Kato Y, Ueda K, Suzuki H, Niinuma K, Tyson CA, et al. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res 1998; 58(22): 513743.
  • 18
    Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997; 33(4): 24559.
  • 19
    Yang T, Lin Y, Chen J, Wang H. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma [Abstract 1054]. In: Programs/Proceedings American Society of Clinical Oncology 36th Annual Meeting, New Orleans, LA, May 20–23, 2000. Alexandria, VA: American Society of Clinical Oncology, 2000.
  • 20
    Kumazawa E, Jimbo T, Ochi Y, Tohgo A. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice. Cancer Chemother Pharmacol 1998; 42(3): 21020.